Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an announcement.
Lumos Diagnostics reported unaudited revenue of US$2.7 million for the quarter to 31 December 2025, down 6.9% on the prior corresponding period, as growth in its flagship FebriDx® product and third‑party CorDx combo tests was unable to fully offset the loss of revenue from its discontinued ViraDx® test. Product revenue came in at US$0.5 million and services revenue held steady at US$2.2 million, supported largely by 12 active customer projects, including the Phase 2 Hologic fFN development program and related IP licensing income. FebriDx® sales rose 4.3 times year-on-year, driven primarily by U.S. demand, while Lumos secured full Medicare reimbursement recognition across the United States and initiated a paediatric study that had enrolled 90 patients by the end of December. The company also advanced its bid for a CLIA waiver for FebriDx®, completing FDA‑requested minor updates to user instructions and a supplemental usability assessment, and remains optimistic that the waiver process is progressing in line with expectations. Lumos ended the quarter with US$3.0 million in cash, down US$1.5 million over three months, and reported an operating cash outflow of US$1.0 million, leaving its undrawn A$5.0 million loan facility as an additional liquidity buffer.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is an Australia-based medical diagnostics company specializing in rapid point-of-care tests, notably its proprietary FebriDx® assay, which helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections from a simple fingerstick blood sample. The company operates a dual model of product sales and services, with a growing focus on the U.S. market where FebriDx is gaining adoption, alongside contract development and IP-licensing projects such as its ongoing work with Hologic on fetal fibronectin (fFN) diagnostics.
Average Trading Volume: 4,173,033
Technical Sentiment Signal: Buy
Current Market Cap: A$182.3M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.